Last update Aug. 18, 2021
Favipiravir is a viral RNA polymerase inhibitor that has been tested to treat influenza A and B viruses, Ebola, Lassa, and coronavirus 2019-nCoV (Joshi 2021, Shiraki 2020).
Oral administration twice a day for 5 days.
At the date of the last update, the authors did not find any published data on its excretion in breast milk.
Its pharmacokinetic data (low molecular weight and low protein binding) make it likely to pass to milk in an amount that could be significant, although the moderately high volume of distribution and high pKa would make it difficult.
Its possible side effects are diarrhea, decreased neutrophils, and elevated transaminases and uric acid (Taisho 2014).
Until more published data is known about this drug in relation to breastfeeding, known safer alternatives may be preferable, especially during the neonatal period and in the event of prematurity.
We do not have alternatives for Favipiravir.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.